MEDIUM confidence: 100% data completeness, but the composite (38) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Low explanatory power (R² 0.09) — the factor model explains little of this stock's return variation, so these exposures are noisy. Interpret with caution.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Net insider -$5.0M over 180 days (0 open-market buys, 8 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $934K— | $240K-74.3% | $622K+159.2% | $15M+2270.6% | $113M+668.3% |
| EPS (dil.) | $-0.89— | $-1.04n/m | $-1.15n/m | $-0.62n/m | $-0.38n/m |
| Free Cash Flow | -$308M— | -$416Mn/m | -$397Mn/m | -$398Mn/m | -$309Mn/m |
| Gross Margin | 100.0% | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 99.3%-0.7pp |
| Operating Margin | -35361.9% | -146374.2%-111012.3pp | -58239.5%+88134.6pp | -2334.2%+55905.3pp | -226.0%+2108.2pp |
| Net Margin | -37129.6% | -173569.6%-136440.0pp | -93761.4%+79808.2pp | -2804.8%+90956.6pp | -310.2%+2494.6pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Buy-rated share 100% → 100% over ~3 months (+0pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $-0.08 | $-0.22 | -175.0% |
| May 2026 | $-0.08 | $-0.62 | -675.0% |
| Feb 2026 | $-0.08 | $-0.06 | +25.0% |
| Nov 2025 | $-0.10 | $-0.07 | +30.0% |
| Aug 2025 | $-0.10 | $-0.10 | +0.0% |
| May 2025 | $-0.12 | $-0.15 | -25.0% |
| Mar 2025 | $-0.26 | $-0.09 | +65.4% |
| Nov 2024 | $-0.18 | $-0.14 | +22.2% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
The QScore of 38 for IBRX suggests a mixed outlook, with the stock's short-term score exceeding its long-term score by 14 points. IBRX scores high on growth and momentum, driven by its remarkable revenue growth of 668.3% and a 12-month return of 239.6%. However, the stock trades at a premium, with negative valuation metrics such as a P/E of -8.5, and exhibits weak profitability, with an operating margin of -151.9% and a negative FCF yield.